Oryzon Genomics S.A. (BME:ORY)

Spain flag Spain · Delayed Price · Currency is EUR
2.610
-0.035 (-1.32%)
Aug 1, 2025, 5:35 PM CET
-1.32%
Market Cap202.31M
Revenue (ttm)7.36M
Net Income (ttm)-4.31M
Shares Out77.51M
EPS (ttm)-0.06
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume344,017
Average Volume508,163
Open2.670
Previous Close2.645
Day's Range2.600 - 2.670
52-Week Range1.400 - 3.690
Beta0.44
RSI36.42
Earnings DateJul 21, 2025

About Oryzon Genomics

Oryzon Genomics S.A., a clinical stage biopharmaceutical company, engages in the discovery and development of epigenetics-based therapeutics for patients with cancer and CNS disorders. Its clinical phase compounds include iadademstat (ORY-1001), a selective LSD1 inhibitor that is in Phase II trials for oncology; and vafidemstat (ORY-2001), a CNS-optimized LSD1 inhibitor, which is in Phase II trials for the treatment of CNS and psychiatric diseases. Its product candidates also comprise ORY-3001, an LSD1 inhibitor that is in preclinical developme... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2000
Employees 47
Stock Exchange Madrid Stock Exchange
Ticker Symbol ORY
Full Company Profile

Financial Performance

In 2024, Oryzon Genomics's revenue was 7.36 million, a decrease of -48.15% compared to the previous year's 14.19 million. Losses were -3.67 million, 9.32% more than in 2023.

Financial Statements

News

Oryzon Genomics S.A. GAAP EPS of -$0.03

2 months ago - Seeking Alpha

Oryzon Genomics S.A. GAAP EPS of -$0.02

5 months ago - Seeking Alpha

ORYZON to Reshape Its Board of Directors at the Upcoming Shareholders' Meeting

Aimed at enhancing U.S. outreach, investor relations, corporate dialogue, and business development (BD) capabilities MADRID and CAMBRIDGE, Mass., Jan. 27, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A...

6 months ago - Benzinga